NCT04328246

Brief Summary

The proposed study assesses the superiority of IES supplementation to the standard of care alone (offloading pressure every two hours) in improving the prevention and treatment of sacral and ischial pressure injuries.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Feb 2021

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 26, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 31, 2020

Completed
11 months until next milestone

Study Start

First participant enrolled

February 26, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 14, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 14, 2022

Completed
Last Updated

January 11, 2023

Status Verified

March 1, 2020

Enrollment Period

1 year

First QC Date

March 26, 2020

Last Update Submit

January 10, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Clinical course of pressure injury over time

    Chauhan Weighted Trajectory Analysis (CWTA) will be used to compare the morbidity associated with sacral and ischial pressure injuries through time. A one-sided Chauhan logrank test at a significance of 0.05 will be used to assess for superiority of the experimental arm over the control arm.

    Patients will be assessed daily for pressure injury location and stage through treatment completion, an average of 14 days.

Secondary Outcomes (8)

  • Clinical course of pressure injury in subgroups

    Patients will be assessed daily for pressure injury location and stage through treatment completion, an average of 14 days.

  • Kaplan-Meier Time-to-Event Analysis

    Final analysis will be performed at end of study (expected completion 2 years)

  • Cox Regression Analysis

    Final analysis will be performed at end of study (expected completion 2 years)

  • Observed Counts of Pressure Injuries

    Final analysis will be performed at end of study (expected completion 2 years)

  • Onset Time

    Final analysis will be performed at end of study (expected completion 2 years)

  • +3 more secondary outcomes

Study Arms (2)

IES Device + Standard of Care

EXPERIMENTAL

Intermittent electrical stimulation system. Charged pulses will be administered to bilateral gluteus maximus through surface electrodes. Stimulation occurs at 30 Hz for 10s every 10 minutes. The intervention is administered 24/7 and added to the standard of care management. Standard of care is defined as turning the patient every two hours.

Device: IES SystemOther: Standard of Care Therapy

Standard of Care

ACTIVE COMPARATOR

Standard of care treatment for pressure injuries is turning the patient every two hours.

Other: Standard of Care Therapy

Interventions

The IES system is composed of a stimulator and self-adhesive surface gel electrodes.

IES Device + Standard of Care

Standard institutional practices for treating pressure injury.

IES Device + Standard of CareStandard of Care

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Modified Braden Scale score of 14 or less. The Modified Braden Scale score is calculated as follows:
  • Braden Scale score (Ranges from 6 to 23)
  • for Low Serum Albumin
  • for Type II Diabetes
  • Anticipated length of stay of at least 4 days
  • BMI \< 35
  • Participants capable of giving informed consent, or if appropriate, participants having an acceptable individual capable of giving consent on the participant's behalf.

You may not qualify if:

  • Existing pressure injuries above Stage II and injuries classified as DTI or unstageable
  • Neuromuscular blocking drugs \& myasthenia gravis: may prevent the ability of electrical stimulation to induce muscular contraction
  • Unstable spinal, pelvic, or hip fractures that may be displaced by a forced contraction
  • Rhabdomyolysis
  • Use of a Pacemaker
  • Skin breakdown over the gluteal regions that would preclude the use of surface electrodes.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

Location

MeSH Terms

Conditions

Pressure Ulcer

Condition Hierarchy (Ancestors)

Skin UlcerSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 26, 2020

First Posted

March 31, 2020

Study Start

February 26, 2021

Primary Completion

March 14, 2022

Study Completion

March 14, 2022

Last Updated

January 11, 2023

Record last verified: 2020-03

Locations